[HTML][HTML] Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on …
S Zeng, D Delic, C Chu, Y Xiong, T Luo, X Chen… - Biomedicine & …, 2022 - Elsevier
To date, the lowest protective SGLT2 inhibitor dose is unknown. We initially performed a
dose-response pilot study in normal rats. Based on the results of this pilot study we …
dose-response pilot study in normal rats. Based on the results of this pilot study we …
Renal protection in chronic heart failure: focus on sacubitril/valsartan
R Pontremoli, C Borghi… - European Heart Journal …, 2021 - academic.oup.com
Chronic kidney disease (CKD) is highly prevalent in patients with chronic heart failure (CHF)
and increases the risk of overall and cardiovascular (CV) mortality. Despite evidence …
and increases the risk of overall and cardiovascular (CV) mortality. Despite evidence …
Treatment of HF in an era of multiple therapies: statement from the HF Collaboratory
AS Bhatt, WT Abraham, JA Lindenfeld, M Bristow… - Heart Failure, 2021 - jacc.org
The treatment of heart failure with reduced ejection fraction (HFrEF) has changed
considerably over time, particularly with the sequential development of therapies aimed at …
considerably over time, particularly with the sequential development of therapies aimed at …
The year in cardiovascular medicine 2020: heart failure and cardiomyopathies
H Bueno, B Moura, P Lancellotti… - European Heart …, 2021 - academic.oup.com
Heart failure (HF) prevalence remains high worldwide with significant sex-related and
regional differences in its presentation, management, and outcomes. In 2020, advances in …
regional differences in its presentation, management, and outcomes. In 2020, advances in …
Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
Y Yao, R Zhang, T An, X Zhao, J Zhang - ESC heart failure, 2020 - Wiley Online Library
Aims This study was to determine the cost‐effectiveness of dapagliflozin in heart failure with
reduced ejection fraction (HFrEF) patients in China from a perspective of health care payers …
reduced ejection fraction (HFrEF) patients in China from a perspective of health care payers …
Recent advances in pharmacological treatment of heart failure
M Iacoviello, A Palazzuoli… - European journal of …, 2021 - Wiley Online Library
Background Over the last years, several trials offered new evidence on heart failure (HF)
treatment. Design and results For HF with reduced left ventricular ejection fraction, type 2 …
treatment. Design and results For HF with reduced left ventricular ejection fraction, type 2 …
Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase …
Importance Sodium glucose cotransporter 2 inhibitors reduce morbidity and mortality in
patients with heart failure and reduced ejection fraction (HFrEF). Clinicians may find …
patients with heart failure and reduced ejection fraction (HFrEF). Clinicians may find …
A practical approach to the guideline‐directed pharmacological treatment of heart failure with reduced ejection fraction
A Abdin, J Bauersachs, S Soltani, M Eden… - ESC Heart …, 2023 - Wiley Online Library
Abstract Over the last 15–20 years, remarkable developments of heart failure (HF)
pharmacotherapies have been achieved. However, HF remains a global healthcare …
pharmacotherapies have been achieved. However, HF remains a global healthcare …
Lower risk of hospitalization for heart failure, kidney disease and death with sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 …
I Idris, R Zhang, JB Mamza, M Ford… - Diabetes, Obesity …, 2021 - Wiley Online Library
Aim To assess if sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) reduce the risk of all‐
cause mortality, cardiovascular death and hospitalization for heart failure (HF) or chronic …
cause mortality, cardiovascular death and hospitalization for heart failure (HF) or chronic …
Efficacy of dapagliflozin according to geographic location of patients with heart failure
T Kondo, X Wang, M Yang, PS Jhund… - Journal of the American …, 2023 - jacc.org
Background Because clinical characteristics and prognosis vary by geographic region in
patients with heart failure (HF), the response to treatment may also vary. A previous report …
patients with heart failure (HF), the response to treatment may also vary. A previous report …